Cargando…
Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis
We herein report a 42-year-old man with advanced lung adenocarcinoma and nivolumab-associated dermatomyositis. Nivolumab, an anticancer drug that is classified as an immune checkpoint inhibitor, often induces immune-related adverse events (irAEs). However, there have so far been no reports regarding...
Autores principales: | Kudo, Fumiaki, Watanabe, Yasutaka, Iwai, Yuki, Miwa, Chihiro, Nagai, Yoshiaki, Ota, Hiromitsu, Yabe, Hiroki, Demitsu, Toshio, Hagiwara, Koichi, Koyama, Nobuyuki, Koyama, Shinichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120830/ https://www.ncbi.nlm.nih.gov/pubmed/29526968 http://dx.doi.org/10.2169/internalmedicine.9381-17 |
Ejemplares similares
-
Early‐stage diffuse panbronchiolitis in a young patient confirmed by video‐assisted lung biopsy: A case report
por: Watanabe, Yasutaka, et al.
Publicado: (2017) -
Pulmonary mucoepidermoid carcinoma arising in a patient with Kartagener syndrome
por: Nagai, Yoshiaki, et al.
Publicado: (2020) -
A young immunocompetent patient with spontaneous Aspergillus empyema who developed severe eosinophilia
por: Kudo, Fumiaki, et al.
Publicado: (2017) -
Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation
por: Koyama, Nobuyuki, et al.
Publicado: (2019) -
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
por: Sekai, Ikue, et al.
Publicado: (2021)